SCHEMBL3464362

SCHEMBL3464362

Cc1n[nH]c(C(F)(F)F)c1[N+](=O)[O-]

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 Q09428 5/20 0.54
KCNJ11 Q14654 5/20 0.54
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
HTT P42858 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
GYS1 P13807 1/20 0.35
MAPT P10636 4/20 0.33
ALDH1A1 P00352 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
PKM P14618 1/20 0.33
CYP3A4 P08684 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29517032 0.79 ABCC8 (0.55) ABCC8KCNJ11GYS1MAPTALDH1A1
SCHEMBL1774571 0.74 HTT (0.51) ADORA2AADORA2BHTTCYP1A2CYP2D6
SCHEMBL31686443 0.74 ADORA2A (0.44) ADORA2AADORA2BHTTCYP1A2CYP2D6
SCHEMBL9912568 0.74 ABCC8 (0.54) ABCC8KCNJ11GYS1MAPTALDH1A1
SCHEMBL9912567 0.73 ABCC8 (0.43) ABCC8KCNJ11MAPTALDH1A1KDM4E
SCHEMBL6684736 0.72 ADORA2A (0.42) ADORA2AADORA2BHTTCYP1A2CYP2D6
SCHEMBL2549734 0.71 ADORA2A (0.41) ADORA2AADORA2BHTTCYP1A2CYP2D6
SCHEMBL9354812 0.71 ADORA2A (0.41) ADORA2AADORA2BHTTCYP1A2CYP2D6
SCHEMBL9357304 0.71 PKM (0.44) ADORA2AADORA2BHTTCYP1A2CYP2D6
SCHEMBL13356463 0.71 ADORA2A (0.41) ADORA2AADORA2BHTTCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933095-B2 KAT II inhibitors PFIZER INC. (US) 2015-01-13 US disclosed
US-8933095-B2 KAT II inhibitors PFIZER INC. (US) 2015-01-13 US disclosed
EP-2646443-B1 KAT II INHIBITORS PFIZER (US) 2014-09-24 EP disclosed
EP-2646443-B1 KAT II INHIBITORS PFIZER (US) 2014-09-24 EP disclosed
US-20140057938-A1 KAT ll INHIBITORS PFIZER INC. (US) 2014-02-27 US disclosed
US-20140057938-A1 KAT ll INHIBITORS PFIZER INC. (US) 2014-02-27 US disclosed
US-8598200-B2 KAT II inhibitors PFIZER INC. (US) 2013-12-03 US disclosed
EP-2646443-A1 KAT II INHIBITORS Pfizer Inc (US) 2013-10-09 EP disclosed
CN-103228660-A Kat II inhibitors PFIZER 2013-07-31 CN disclosed
US-8324216-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2012-12-04 US disclosed
US-20120302599-A1 KAT ll INHIBITORS PFIZER INC 2012-11-29 US disclosed
WO-2012073143-A1 KAT II INHIBITORS PFIZER INC. (US) 2012-06-07 WO disclosed
WO-2012073143-A1 KAT II INHIBITORS PFIZER INC. (US) 2012-06-07 WO disclosed
US-20100240618-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2010-09-23 US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 US disclosed
EP-1691810-A4 SUBSTITUTED PIPERAZINES CHEMOCENTRYX INC (US) 2009-07-01 EP disclosed
EP-1691810-A1 SUBSTITUTED PIPERAZINES ChemoCentryx Inc (US) 2006-08-23 EP disclosed
US-20060106218-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2006-05-18 US disclosed
US-20050256130-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2005-11-17 US disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106218-A1 Substituted piperazines CCR1, CCR3, CCRL2 ABCC8 1854/4885KCNJ11 4238/4885ADORA2A 847/4885
US-20140057938-A1 KAT ll INHIBITORS KAT2A, KAT7, KAT5 ABCC8 3928/4885KCNJ11 1485/4885ADORA2A 4716/4885
US-20050256130-A1 Substituted piperazines CCR1, CCR3, CCRL2 ABCC8 1854/4885KCNJ11 4238/4885ADORA2A 847/4885
US-20120302599-A1 KAT ll INHIBITORS KAT2A, KAT7, KAT5 ABCC8 3928/4885KCNJ11 1485/4885ADORA2A 4716/4885
US-20100240618-A1 SUBSTITUTED PIPERAZINES CCR1, CCR3, CCRL2 ABCC8 1854/4885KCNJ11 4238/4885ADORA2A 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.